Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives
about
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisAmphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Quantifying clinical relevance in the treatment of schizophrenia.Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.A Meta-analytic Review of Non-specific Effects in Randomized Controlled Trials of Cognitive Remediation for SchizophreniaAntipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Transdiagnostic Clinical Global Impression Scoring for Routine Clinical SettingsRole of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI).What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
P2860
Q24606868-B0A3EFB9-47AD-4F94-9DFF-B6C91DC3F22EQ30439296-8BD2282A-62CD-4488-AAD1-D38B896EB84EQ34418847-CB797F67-D661-4649-BB2F-5B79614E8ECFQ35819467-20AF2A7A-7FE1-4334-97EB-646AD06499DAQ35828559-9075933D-64F9-4FCE-962A-E7E73ADEBC56Q36260429-A82DECC2-3B8D-4F13-83A3-0E33A491B2B2Q37029622-ABF94086-44AB-41F5-8DE8-53413FCCA7C6Q37451403-22D81B7D-250B-40F9-8C7D-8D6B581A29BAQ41663038-BDA85F96-B295-458A-822E-F0EF8AE42B33Q47154075-1135B249-C310-43E9-870F-DE625817C7D1Q49706763-38A0FF5D-F6D2-46D2-A843-7EEA9F1A1333Q55023835-7415126B-888C-43A6-80B1-7A0C42B2255AQ57817726-8A5B77B8-39F0-44A4-9FF5-9F8F96E3F250
P2860
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Randomized controlled trials i ...... and trial design alternatives
@ast
Randomized controlled trials i ...... and trial design alternatives
@en
Randomized controlled trials i ...... and trial design alternatives
@nl
type
label
Randomized controlled trials i ...... and trial design alternatives
@ast
Randomized controlled trials i ...... and trial design alternatives
@en
Randomized controlled trials i ...... and trial design alternatives
@nl
prefLabel
Randomized controlled trials i ...... and trial design alternatives
@ast
Randomized controlled trials i ...... and trial design alternatives
@en
Randomized controlled trials i ...... and trial design alternatives
@nl
P2093
P2860
P1476
Randomized controlled trials i ...... and trial design alternatives
@en
P2093
Christoph U Correll
John M Kane
Taishiro Kishimoto
P2860
P304
P407
P577
2011-01-01T00:00:00Z